Asthma Clinical Research Network Trial (ACRN) - Macrolides in Asthma (MIA)
Note that you will be prompted to log in or register an account
Open BioLINCC Study See bottom of this webpage for request information
July 2006 - March 2009
March 12, 2013
March 12, 2013
Clinical Trial URLs
Primary Publication URLs
Commercial Use Data Restrictions No
Data Restrictions Based On Area Of Research No
To test the hypothesis that clarithromycin would improve asthma control in individuals with mild-to-moderate persistent asthma that was not well-controlled despite treatment with low-dose inhaled corticosteroids (ICS).
Research has shown that in some individuals, respiratory airway infections may play a role in the onset and severity of asthma. Inhaled corticosteroids are commonly used to treat asthma; however, they do not effectively control symptoms for everyone. Clarithromycin, an antibiotic medication used to treat bacterial infections, may be an effective asthma treatment for individuals who do not respond well to inhaled corticosteroids.
Participants were eligible if they had a clinical diagnosis of asthma and either bronchodilator responsiveness, defined as an increase of 12% or greater in the forced expiratory volume in one second (FEV1) 15 minutes after the administration of two puffs of albuterol, or airway hyperresponsiveness, measured by the PC20 FEV1 to methacholine (the concentration of methacholine inducing a 20% fall in FEV1) of ≤ 16 mg/mL. Participants also were required to demonstrate suboptimally-controlled asthma at the time of enrollment, as defined by threshold scores on the Juniper Asthma Control Questionnaire (ACQ) of ≥ 1.5 in those not receiving inhaled corticosteroid (ICS)-containing treatments. Participants receiving ICS-containing treatments could be enrolled with an ACQ score ≥ 1.25 at enrollment or if in the opinion of the investigator the ACQ score was likely to be ≥ 1.25 at the end of the run-in period.
Ninety-two participants were randomized. Twelve (13%) subjects demonstrated PCR evidence of M. pneumoniae or C. pneumoniae in endobronchial biopsies; 80 were PCR negative for both organisms.
Adults with an Asthma Control Questionnaire (ACQ) score ≥1.5 after a 4 week period of treatment with fluticasone propionate were entered into a PCR-stratified randomized trial to evaluate the effect of 16 weeks of either clarithromycin or placebo, added to fluticasone, on asthma control in individuals with or without lower airway PCR evidence of M. pneumoniae or C. pneumoniae.
Adding clarithromycin to fluticasone in adults with mild-to-moderate persistent asthma that was suboptimally-controlled by low-dose ICS alone did not further improve asthma control. Although there was an improvement in airway hyperresponsiveness with clarithromycin, this benefit was not accompanied by improvements in other secondary outcomes. (J Allergy Clin Immunol, 2010; 126(4): 747–753)
Please note that researchers must be registered on this site to submit a request, and you will be prompted to log in. If you are not registered on this site, you can do so via the Request button. Registration is quick, easy and free.
Resources AvailableStudy Datasets Only
Persons using assistive technology may not be able to fully access information in the study documents. For assistance, Contact BioLINCC and include the web address and/or publication title in your message. If you need help accessing information in different file formats such as PDF, XLS, DOC, see Instructions for Downloading Viewers and Players.